What makes ViiV Healthcare unique is our sole focus on HIV. By combining breakthrough science with a deep understanding of the people and communities we serve, we have the opportunity to redefine the future of HIV treatment, prevention and cure research, helping to ensure no person living with HIV is left behind.
Charlotte Allerton
Head of Research and Development, ViiV Healthcare
Head of Research & Development and Chief Scientific Officer for ViiV Healthcare, Charlotte Allerton oversees the discovery and clinical development of our pipeline assets in support of our overall company strategy to deliver meaningful advances in treatment and care for people living with HIV.
Charlotte is a globally accomplished scientist who is known for her strong and compassionate leadership and successful track record in drug discovery and development. Her career started at Pfizer where she joined as a medicinal chemist and most recently served as Senior Vice President and Head of Preclinical and Translational Science. A driving force behind the discovery and development of an oral antiviral for COVID19 during her time at Pfizer, she and her team earned multiple honors, including the prestigious Prix Galien and ACS Heroes of Chemistry awards. For the last four years, she has been an important member of the ViiV Healthcare Board of Directors and strongly believes in our purpose and patient focus.
Charlotte's contributions to the field have been recognised. She is an honorary fellow of the Royal Society of Chemistry. In 2020, she received the Healthcare Businesswomen's Association Luminary award, and in 2024 she was recognized on the Medicine Maker Power List. Charlotte earned a Bachelor of Science degree from the University of Nottingham and a Master of Philosophy in organic chemistry from the University of Cambridge.
Charlotte's achievements
2026
Joined ViiV Healthcare as Head of Research and Development
2024
Received Prix Galien Award for best Pharmaceutical Product and recognised on the Medicine Maker Power List
2022 – 2026
Served as a member of the ViiV Healthcare Board of Directors In 2022, accepted ACS Heroes of Chemistry Award
2021
Recognised as an Honorary Fellow of the Royal Society of Chemistry for her impact on scientific advancement and leadership in the field of chemical science
2020
Received the Healthcare Businesswomen's Association Luminary award
2006 – 2026
Led global teams at Pfizer across a range of therapy areas and disciplines in drug discovery and development, most recently as Head of Discovery and Early Development
